Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation

Delabaudière, Cyrielle; Lavayssière, Laurence; Dörr, Gaëlle; Muscari, Fabrice; Danjoux, Marie; Sallusto, Fédérico; Péron, Jean Marie; Bureau, Christophe; Rostaing, Lionel; Izopet, Jacques; Kamar, Nassim

doi:10.1111/tri.12428

Cited by 23 publications

(19 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clearance of HCV was observed by 4 weeks of treatment, with excellent tolerance. 55 The FDA have approved a combination of ledipasvir and sofosbuvirthe first oncedaily single tablet regimen for the treatment of chronic infection with HCV genotype 1. 56 The development of these new drugs might change the natural history of HCV infection in dialysis and after renal transplantation.…”

Section: Novel Perspectivesmentioning

confidence: 99%

Hepatitis C and its impact on renal transplantation

Morales

Fabrizi

2015

Nat Rev Nephrol

View full text Add to dashboard Cite

Infection with hepatitis C virus (HCV) is the major cause of chronic liver disease that occurs after renal transplantation. Such infection is often acquired during dialysis while patients wait to undergo renal transplantation. Renal transplantation is considered the best treatment option for patients with HCV infection and end-stage renal disease, although acceptance of a kidney graft by the host immune system and patient survival are lower compared to patients who test negative for HCV. The approval of interferon-free therapies could substantially change the natural history of HCV infection after renal transplantation. This Review discusses the interplay between renal transplantation, HCV infection, and liver disease. We emphasize the development of novel therapeutic strategies, including use of the newly identified direct-acting antiviral agents for treating hepatitis C among infected patients. We next analyse the most common clinical complications subsequent to HCV infection and the impact on graft and patient survival. Finally, we evaluate the consequences of kidney transplantation from HCV-positive donors.

show abstract

Section: Novel Perspectivesmentioning

confidence: 99%

Hepatitis C and its impact on renal transplantation

Morales

Fabrizi

2015

Nat Rev Nephrol

View full text Add to dashboard Cite

show abstract

“…79 These concerns may be diminished by recent data from liver recipients showing successful treatment of fibrosing cholestatic hepatitis using current DAAs. [80][81][82][83] These results are encouraging; however, we await confirmation of these outcomes in kidney recipients.…”

Section: Grazoprevir and Elbasvirmentioning

confidence: 99%

Hepatitis C Virus Infection in Chronic Kidney Disease

Ladino

Pedraza

Roth

2016

JASN

View full text Add to dashboard Cite

Soon after the hepatitis C virus (HCV) was identified in 1989, it was recognized that the prevalence of infection in patients with ESRD far exceeded that in the general population. Infection with HCV predisposes to the hepatic complications of cirrhosis and hepatocellular carcinoma. However, important extrahepatic manifestations include immune complex glomerular disease, accelerated progression of CKD, increases in cardiovascular event risk, and lymphoproliferative disorders. Advances in understanding the molecular biology of HCV have ushered in a new era in the treatment of this infection. Second generation direct-acting antiviral agents have revolutionized therapy, with sustained virologic response rates (undetectable viral load 12 weeks after completing therapy) of .90% in most patients. Studies using direct-acting antivirals in patients with CKD and those on dialysis are showing excellent safety and efficacy as well. In this context, it is imperative that nephrologists become familiar with this literature, reviewed here, so that the important decisions, including which patients should be treated and the optimal timing to initiate therapy, are vetted in association with the compounding issues of CKD, ESRD, and kidney transplantation.

show abstract

“…Clearance of HCV was observed by week 4 of treatment with excellent tolerance. 69 The US Food and Drug Administration have approved a combination of ledipasvir and sofosbuvir, the first once-daily single tablet regimen for the treatment of chronic infection with HCV genotype 1. 70 The development of these new drugs might change the present course of HCV infection in dialysis and renal transplant patients.…”

Section: New Anti-hepatitis C Virus Agentsmentioning

confidence: 99%

Untitled

Gheith

Halim²,

Othman³

et al. 2017

Exp Clin Transplant

View full text Add to dashboard Cite

Chronic hepatitis C virus infection is a global health problem, especially among renal transplant recipients. Herein, we present an overview of hepatitis C virus among renal transplant patients, with a focus on some updated aspects concerning types of viral genotypes, methods of diagnosis, the effects of renal transplant on hepatitis C virus infection, and summary of hepatitis C virus-related complications after renal transplant. We also discuss patient and graft survival rates and the present and future therapeutic options with special focus on new antiviral and possible interactions with immunosuppressive medications.

show abstract

Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation

Cited by 23 publications

References 14 publications

Hepatitis C and its impact on renal transplantation

Hepatitis C and its impact on renal transplantation

Hepatitis C Virus Infection in Chronic Kidney Disease

Untitled

Contact Info

Product

Resources

About